| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8003679 | BOEHRINGER INGELHEIM | Use of inhibitors of the renin-angiotensin system |
Oct, 2022
(11 months ago) | |
Micardis is owned by Boehringer Ingelheim.
Micardis contains Telmisartan.
Micardis has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Micardis are:
- US8003679
Micardis was authorised for market use on 10 November, 1998.
Micardis is available in tablet;oral dosage forms.
Micardis can be used as treatment or prevention of stroke.
The generics of Micardis are possible to be released after 06 October, 2022.
Drugs and Companies using TELMISARTAN ingredient
Market Authorisation Date: 10 November, 1998
Treatment: Treatment or prevention of stroke
Dosage: TABLET;ORAL
MICARDIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic